Key Takeaways
- Volume-led growth, margin lag: Pharma food & nutrition volumes rose >20% but EBITDA growth underwhelmed because new products ran on sub-scale lines and a recruitment cycle loaded costs ahead of revenue.
- Specialty ingredients is the breakout vertical: Revenue jumped 62% to ₹280 cr, driven by encapsulation and premix approvals with top global bakery and infant nutrition accounts.
- Battery materials is now a real, dated catalyst: Phase 1 (25,000 MT) commissioning is on track for April 2027, with 700 MT of early orders already booked and a 5,000–7,000 MT pilot line running.
- Working capital stretched deliberately: Days rose from 184 to 213 as the company built strategic inventory to secure supply continuity and support customer commitments in Europe and the US.
- What to watch next quarter: Whether the greenfield facility starts converting customer approvals into volume and margin, the pace of inventory liquidation toward the 150–160 day target, and any quantification of battery material revenue contribution for FY27.
Pharma Food & Nutrition: The Volume-Margin Disconnect
- Volume story is real: Quantity growth exceeded 20%, with phosphate capacity running at optimum utilisation and India and Europe leading geographic expansion.
- Mix shift diluted realisation: Phosphate price increases were only passed on in Q1, with March and April orders honoured at old prices, so the pricing benefit is partial in Q1 and flows more fully in Q2.
- New products are margin-dilutive at current scale: Glycinate and gluconate molecules carry higher operational costs because they run on temporary, smaller lines with low capacity utilisation; margins should improve once production moves to the greenfield facility.
- Costs loaded ahead of revenue: A significant recruitment cycle to staff the new greenfield sits in this vertical's cost base before the facility generates revenue, further compressing near-term EBITDA.
- Growth expectation set: Management is "comfortably positioned" to deliver ~15% EBITDA growth in both FY27 and FY28, with Europe and North America called out as prior underperformers now turning.
Shanil Bhayani: "The quantity volume growth is north of 20% in this category. What we are seeing is for phosphate specifically, the price increase we have only passed on to the customers in Q1. So we have continued to honor the orders in March and April."
Specialty Ingredients: The High-Growth Engine
- 62% revenue growth to ₹280 cr made this the fastest-growing vertical, led by product expansion, wallet share gains, and new customer approvals.
- Encapsulation technology wins: Approval secured with the largest bakery globally in the last financial year, plus two more of the top five; this technology is a proprietary in-house build.
- Premix category breakthrough: Approved with the largest infant nutrition company, opening a large, sticky revenue stream in a high-barrier segment.
- End-market breadth: Strong traction spans infant nutrition, medical nutrition, sports nutrition, and dietary supplements, diversifying the vertical's demand base.
- Margin profile is structurally higher: Specialty ingredients will continue to sustain a stronger margin profile than the pharma food & nutrition average, pulling up the overall business margin as it scales.
Battery Materials: The April 2027 Catalyst
- Phase 1 on track: Groundbreaking completed at Dahej; 25,000 MT per year capacity is scheduled for commissioning by April 2027, with a total target of 100,000 MT and ₹600 cr in associated capex.
- Early commercial traction: 700 MT of orders already received across domestic and global customers, and a 5,000–7,000 MT pilot line is commissioned within the existing pharma facility.
- China Plus One positioning: Management is explicit that the goal is not to compete with China on cost; the product is engineered for superior battery performance against Chinese iron phosphate, and the value proposition rests on supply chain diversification, geopolitical considerations, and regulatory requirements for ex-China sourcing.
- Demand visibility building: Confidence in filling Phase 1 capacity is rising based on customer engagement, qualification progress, and commercial discussions; energy storage for AI-driven data centres is flagged as a major long-term growth driver.
- Financial profile will be different: Management warns that battery materials will operate with distinct working capital dynamics, margin structure, and scalability metrics versus the core pharma business, and declined to disclose specifics to safeguard competitive information.
Shanil Bhayani: "The goal is not to compete with China. Our focus right from the beginning since we started this business has been to give a product which has, which is highly competitive from a performance perspective against the Chinese iron phosphate because 100% of iron phosphate today is manufactured in China."
Greenfield & NSS: The Capacity and Platform Build-Out
- Greenfield commissioned: Internal production validation and qualification are complete; the customer approval process is now underway, with qualification timelines of 6–12 months depending on product category and audit requirements.
- Capability upgrade: The facility will significantly strengthen manufacturing infrastructure for higher-value molecules (gluconates, glycinates, citrates), enabling the next phase of growth for pharma food & nutrition.
- NSS integration progressing: Operations and supply chain integration is smooth; a new business head with 30+ years in European pharma and nutrition ingredients has been appointed to accelerate expansion outside Ireland, particularly in infant nutrition and critical care.
- 51 new customer approvals secured in FY26 are expected to contribute meaningfully to growth in FY27, spanning both verticals.
Margins: The Recovery Path
- FY26 EBITDA margin fell to 34.6% from 37.8% in FY25, a ~200 bps decline driven by investments in building commercial teams across Europe and North America.
- Q4 other expenses spiked on one-time items: ₹3 cr CSR expenditure, ₹1.5 cr LPG premium from a shortage (specialty ingredients runs on LPG), and ₹2 cr air freight to the largest customer due to production delays from lower capacity.
- Recovery commitment: Management expects margins to track back to FY24/FY25 levels in the next couple of quarters, with the newly built commercial teams beginning to contribute positively; when asked directly if margins can reach 37–38% in FY27, management confirmed.
- Bisglycinate is the medium-term margin lever: The new molecule carries higher realisation (management noted four times the realisation of current products but declined to give a precise premium), with FY27 as the first year of scale production and higher margin contribution expected from FY28.
Shanil Bhayani: "From a margin perspective, we will not talk too much today about the battery as well as the new molecules that we bring into market, right? We have to also safeguard our, I mean, not to make everything too public because our suppliers, customers, everyone would have access to this information."
Working Capital & Raw Material Management
- Net working capital days rose from 184 to 213, driven by a deliberate inventory build: ₹37 cr in finished goods to support customer commitments in Europe and the US, and ₹41 cr in raw materials to ensure supply continuity amid phosphoric acid price volatility and a contract expiry in March 2026.
- Phosphoric acid pass-through worked: A sharp increase in input costs (driven by higher global sulfur prices) was successfully passed to customers without material margin compression, reflecting the critical, functional role of the ingredients and strong customer stickiness.
- Normalisation target: Management is targeting a net working capital cycle of 150–160 days within FY27, with inventory liquidation expected in the current and upcoming quarters.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pharma food & nutrition EBITDA growth | ~15% growth | FY27 and FY28 |
| Overall margin recovery | Track back to FY24/FY25 levels (37–38% EBITDA) | Next couple of quarters |
| Net working capital days | Normalise to 150–160 days | Within FY27 |
| Battery materials Phase 1 commissioning | 25,000 MT capacity online | April 2027 |
| Battery materials volume (analyst assumption) | ~2,500 MT in FY27 called a "fair assumption" | FY27 |
| Bisglycinate margin contribution | Higher margin contribution begins | Starting FY28 |
| Greenfield customer qualifications | Approval process underway | 6–12 months depending on product |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations | ₹182.3 cr, +15.7% YoY |
| EBITDA | ₹62.6 cr, vs ₹58.8 cr in Q4 FY25 |
| EBITDA margin | 34.3% |
| PAT | ₹48.5 cr, vs ₹44.2 cr in Q4 FY25 |
| Revenue from operations (FY26) | ₹642.3 cr, +27.9% YoY |
| EBITDA (FY26) | ₹221.9 cr, +16.8% YoY |
| EBITDA margin (FY26) | 34.6%, vs 37.8% in FY25 |
| PAT (FY26) | ₹174.3 cr, vs ₹138.7 cr in FY25 |
| Specialty ingredients revenue (FY26) | ₹280 cr, +62% YoY; 44% of FY26 revenue vs 34% in FY25 |
| Pharma food and nutrition revenue growth (FY26) | 10% YoY; volume growth north of 20% |
| Export contribution (FY26) | 60% of revenue; domestic 40% |
| New customer approvals (FY26) | 51, vs FY25 |
| Battery materials purchase orders received | ~700 metric tons over the last month; 6 customers completed commercial validation |
| Battery materials Phase 1 capacity | 25,000 metric tons per year, commissioning by April 2027 |
| Net debt | ₹33.6 cr as of 31st March 2026; net debt-to-equity 0.04x |
| Working capital days | 213 days in FY26, vs 184 days in prior year; targeting 150-160 days in FY27 |
| Inventory increase | ₹88 cr YoY; raw material +₹41 cr, finished goods +₹37 cr |
| Gross capex spent (FY26) | ₹127 cr; SAM land ₹34 cr, greenfield ₹80 cr, maintenance ~₹13 cr |
| FY27 core business capex outlook | ~₹25 cr; ~₹10 cr for greenfield completion, ~₹15 cr maintenance |
| Pharma food and nutrition capacity utilization | 65% to 70% (without greenfield) |
| Specialty ingredients capacity utilization | 35% to 40% |
| One-time Q4 cost impacts | ₹3 cr CSR expenditure, ₹1.5 cr higher power and fuel (LPG premium), ₹2 cr air freight impact in selling and distribution |